Chemical subgroup
L02BB – Antiandrogene
9Decisions
9Patient groups
Added benefit by patient group
- Considerable4
- Minor2
- Not proven3
Decisions, newest first
- 2026-02-19NubeqaDarolutamidNot proven
- 2023-09-21NubeqaDarolutamidConsiderable
- 2021-11-19XtandiEnzalutamidNot proven
- 2020-11-05XtandiEnzalutamidMinor
- 2020-10-15NubeqaDarolutamidConsiderable
- 2020-10-01ErleadaApalutamidMinor
- 2020-08-20ErleadaApalutamidNot proven
- 2015-06-18XtandiEnzalutamidConsiderable
- 2014-02-20XtandiEnzalutamidConsiderable
Data status: 2026-10-29